Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma.
about
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myelomaThalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.Bortezomib: the evidence of its clinical impact in multiple myeloma.Repeat administration of high dose melphalan in relapsed myeloma.Mechanisms of action and resistance to tubulin-binding agents.Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.Acquired activated protein C resistance and thrombosis in multiple myeloma patientsThe current position of allogeneic and autologous BMT in multiple myeloma.Evolving treatment strategies for myeloma.VAD chemotherapy as remission induction for multiple myeloma.Multiple myeloma: current treatment.Haematology.The role of high-dose chemotherapy followed by peripheral blood stem cell transplantation for the treatment of multiple myeloma.Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myelomaDouble autologous stem cell transplantation for multiple myeloma: a Korean single center study.Cucurbitacin B exerts anti-cancer activities in human multiple myeloma cells in vitro and in vivo by modulating multiple cellular pathways.Guidelines for the diagnosis and management of multiple myeloma 2011.Improved survival in multiple myeloma, with a diminishing racial gap and a widening socioeconomic status gap over three decades.Is there a role for 'modified VAD' in the treatment of multiple myeloma?Proteomic evaluation of pathways associated with dexamethasone-mediated apoptosis and resistance in multiple myeloma.Evolving strategies for the treatment of myelomatosis.Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.Multiple myeloma presenting clinically as lymphoma.The treatment of multiple myeloma--an important MRC trial.The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.Diagnosis and management of multiple myeloma.Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.Impact of early response to sequential high-dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features.Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment.VAD regimen in the treatment of resistant multiple myeloma: slow or fast infusion?A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.Reversible ageusia after chemotherapy with pegylated liposomal doxorubicin.Guidelines on the diagnosis and management of AL amyloidosis.Detection of minimal residual myeloma after bone marrow transplantation.Vincristine, Adriamycin and Dexamethasone (VAD) as Primary Therapy in Advanced Multiple Myeloma: A Single Centre Experience.Reduced risk of bacterial infection in multiple myeloma patients with VAD regimen without intermittent high-dose dexamethasone.Guidelines on the diagnosis and management of multiple myeloma 2005.A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.Low dose oral idarubicin in combination with cyclophosphamide and dexamethasone (CID) for management of melphalan-prednisolone (MP) resistant myeloma.
P2860
Q28194391-E18754BD-5F8A-4F86-AA00-4CA0705E9564Q33364235-11650B82-74B9-4EDC-8C51-00652CB40A74Q33400724-A997BC92-9704-4FA0-B7E5-ED93DECA98CAQ33492940-02DF6A19-9ED4-4816-B47C-0B0ACBE7085BQ34074808-82D87777-0F75-423B-80CF-5A47E0B40316Q34753416-CE06C5B8-8CB5-433E-8499-055A4A078EA4Q35024872-CDE37C25-3EB3-43EC-804C-F638BF7401E1Q35166734-D737816B-80E0-429D-8D60-231F6BA42925Q36012354-8B618247-F4C7-48F4-A524-9F10704F4ED1Q36080450-0E04D8B5-D4D2-49C4-9906-10A1AE42E99AQ36679167-86875C6A-1D95-4C84-B03B-FAD015C42567Q36723863-5C868F42-0CF6-4784-836F-8ED1531F95F1Q37209935-28C0F3D6-5364-44CA-924A-52DB7B183311Q37274353-E13A4868-73CC-440D-9D4C-5CE94C280611Q37476203-4F4CFBFE-A905-4796-A91D-DBA12AB723BFQ37701484-8F4FCCC6-01CF-4143-AA7E-F7B96E0DEF0CQ37875193-DC610245-DB90-4AC0-9547-3F1CDE536CCFQ38735921-ADC1062C-65B7-4AA8-98CA-996FDA04F91FQ39370010-D5EF557A-8731-402D-AD24-2017D748454AQ40057665-5F73357F-B1CD-4F7F-ADBD-513F68D94D81Q40567869-A74D0A2D-9052-44AC-863F-6AE46D17C819Q40639156-45F044D0-4EDE-4436-AE4C-7CCD663E848AQ40641184-4A56B587-51B0-415C-A2C5-5FAC25427814Q42590412-C19EDCA5-89C7-4E01-9B9E-FB6EED27BB36Q43548692-2DBD07DD-0678-4641-AB91-8AB1C402D6A1Q43817786-5826720D-E7F7-494F-9AB1-C4775D1D27D6Q43885601-F10FD6DB-A362-4E96-AFD0-B0865D257ECBQ43973073-5B26EF0A-1A5C-43DD-A606-46E8F7411742Q43987783-B711F502-5C5F-45F8-8DAC-913A41DCED39Q44004543-93871F41-5B30-42D2-AAD4-2B4091E37B05Q44042850-D3CE685F-D69A-4E35-9FC2-12747AEECB22Q44083946-1D55B57C-8171-4F35-9A5B-9D30D86BB2DBQ44909744-326826F8-ECDC-43A5-BB3D-0EA1E46EF8A8Q44924110-B9567371-56D0-46D3-8ADF-274009CAEC41Q45139195-1C599C6B-DA48-47A8-81B7-09BB054905DAQ46189595-937D4F7D-7CED-4ADB-BE8C-C183E39B6B8DQ53162297-E298EB26-442A-4F41-9902-E9170E2D93BCQ53556535-54B4647C-D494-4233-BF34-EFEC003C8AFCQ53951659-8545D356-7B35-4506-90BA-D8BA1589344AQ54098130-BCE23B89-916A-472B-AE22-0EEC7BEA189C
P2860
Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh-hant
name
Infusion of vincristine and do ...... therapy for multiple myeloma.
@en
Infusion of vincristine and do ...... therapy for multiple myeloma.
@nl
type
label
Infusion of vincristine and do ...... therapy for multiple myeloma.
@en
Infusion of vincristine and do ...... therapy for multiple myeloma.
@nl
prefLabel
Infusion of vincristine and do ...... therapy for multiple myeloma.
@en
Infusion of vincristine and do ...... therapy for multiple myeloma.
@nl
P2093
P1433
P1476
Infusion of vincristine and do ...... therapy for multiple myeloma.
@en
P2093
D McCarthy
E Gaminara
J Van de Pette
T Mitchell
P304
P356
10.1016/S0140-6736(89)91549-3
P407
P577
1989-10-01T00:00:00Z